经典霍奇金淋巴瘤 (CHL) 的特点是炎症背景下罕见的肿瘤性霍奇金细胞和里德-斯滕伯格 (HRS) 细胞。使用流式细胞术和免疫组织化学 (IHC) 探讨 CC 趋化因子受体 7 (CCR7) 在 CHL 中的诊断效用。对肿瘤标本和非肿瘤性淋巴结进行免疫表型分析，并通过流式细胞术（克隆 3D12）和 IHC 半定量测量 CCR7 表达（克隆 150503）。我们的结果表明，绝大多数 CHL 病例中 CCR7 在 HRS 细胞上表达（流式细胞术检测为 45/48，IHC 检测为 57/59），但在弥漫性大 B 细胞淋巴瘤的肿瘤细胞中很少表达，未另外指定的（流式细胞术为 1/25，IHC 为 2/40）和结节性淋巴细胞为主的霍奇金淋巴瘤（流式细胞术为 0/4，IHC 为 1/13）。原发性纵隔大 B 细胞淋巴瘤 (PMLBCL) 在大多数情况下 (8/10) 经流式细胞术检测显示 CCR7 表达较弱，但 IHC 检测仅偶尔显示弱 CCR7 表达 (2/12)。与 IHC (0/7) 相比，两例 (2/2) 富含 T 细胞/组织细胞的大 B 细胞淋巴瘤 (THRLBCL) 也通过流式细胞术检测到 CCR7 表达。通过 IHC 检测，HRS 细胞显示出比其他 B 细胞淋巴瘤更高的阳性细胞百分比和更高的抗原强度。通过流式细胞术在 PMLBCL 和 THRLBCL 中鉴定出的表达，但通过 IHC 鉴定不到的表达表明，这两种技术或所使用的 2 个 CCR7 克隆的检测能力可能存在差异。HRS 细胞中 CCR7 的表达表明其在区分 CHL 和 CHL 方面具有潜在用途。其他 B 细胞淋巴瘤。将 CCR7 纳入流式细胞术和 IHC 组合可能会进一步提高 CHL 的诊断灵敏度。© 作者 2024。由牛津大学出版社代表美国临床病理学会出版。版权所有。如需商业重复使用，请联系 reprints@oup.com 获取转载和转载的翻译权。所有其他权限都可以通过我们网站文章页面上的权限链接通过我们的 RightsLink 服务获得 - 如需更多信息，请联系journals.permissions@oup.com。

Classic Hodgkin lymphoma (CHL) is characterized by infrequent neoplastic Hodgkin and Reed-Sternberg (HRS) cells in an inflammatory background. The diagnostic utility of CC-chemokine receptor 7 (CCR7) in CHL was explored using flow cytometry and immunohistochemistry (IHC).Neoplastic specimens and non-neoplastic lymph nodes were immunophenotyped and CCR7 expression was measured semiquantitatively by flow cytometry (clone 3D12) and IHC (clone 150503).Our results showed that CCR7 was expressed on HRS cells in the vast majority of CHL cases (45/48 by flow cytometry, 57/59 by IHC) but rarely expressed in neoplastic cells in diffuse large B-cell lymphoma, not otherwise specified (1/25 by flow cytometry, 2/40 by IHC) and nodular lymphocyte predominant Hodgkin lymphoma (0/4 by flow cytometry, 1/13 by IHC). Primary mediastinal large B-cell lymphoma (PMLBCL) revealed weak CCR7 expression by flow cytometry in most cases (8/10) but only occasionally by IHC (2/12). Both cases (2/2) of T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) also showed CCR7 expression detected by flow cytometry compared with IHC (0/7). The HRS cells demonstrated a greater percentage of positive cells and greater antigen intensity than the other B-cell lymphomas by IHC. The expression identified by flow cytometry in PMLBCL and THRLBCL but not by IHC suggests that there may be differences in the detection capabilities of the 2 techniques or the 2 CCR7 clones used.The expression of CCR7 in HRS cells suggests its potential utility in differentiating CHL from other B-cell lymphomas. Incorporating CCR7 into flow cytometry and IHC panels may further enhance the diagnostic sensitivity of CHL.© The Author(s) 2024. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.